AIP
ACTU

Ameritas Investment Partners’s Actuate Therapeutics ACTU Stock Holding History

Ameritas Investment Partners’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.65K Hold
601
– – ﹤0.01% 3077
2025
Q4 		$3.68K Hold
601
– – ﹤0.01% 3060
2025
Q3 		$4.02K Hold
601
– – ﹤0.01% 3077
2025
Q2 		$3.67K Buy
+601
New +$5.25K ﹤0.01% 3129

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's ACTU Position: Q1 2026 in Review

Ameritas Investment Partners held its Actuate Therapeutics (ACTU) position steady in Q1 2026 at 601 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3077.

Ameritas Investment Partners first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.02K in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Ameritas Investment Partners held 601 shares of Actuate Therapeutics worth $1.65K as of Q1 2026.
  • Ameritas Investment Partners left its Actuate Therapeutics share count unchanged in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #3077 holding.
  • Ameritas Investment Partners first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameritas Investment Partners's Actuate Therapeutics position peaked at $4.02K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.